

# Standard Specification for Identification of Vials and Ampoules Containing Concentrated Solutions of Drugs to be Diluted Before Use<sup>1</sup>

This standard is issued under the fixed designation D 5022; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon ( $\epsilon$ ) indicates an editorial change since the last revision or reapproval.

## 1. Scope

1.1 This specification deals with identification of small volume containers of drugs intended to be diluted before parenteral administration, as follows:

- 1.1.1 Container shape,
- 1.1.2 Labeling statements,
- 1.1.3 Vial closures and Flip-Off,<sup>2</sup> type caps, and
- 1.1.4 Ampoule marking.

## 2. Referenced Documents

### 2.1 ASTM Standards:

- D 996 Terminology of Packaging and Distribution Environments<sup>3</sup>
- D 4267 Specification for Labels for Small Volume (Less than 100 mL) Parenteral Drug Containers<sup>3</sup>
- D 4775 Specification for Identification and Configuration of Prefilled Syringes and Delivery Systems for Drugs (Excluding Pharmacy Bulk Packages)<sup>3</sup>

### 2.2 Other Standards:

- Pantone Matching Systems Current Edition<sup>4</sup>

## 3. Terminology

3.1 General definitions for packaging and distribution environments are found in Terminology D 996.

3.2 *ampoule*—a hermetically sealed, small bulbous glass or plastic vessel; opening is achieved by breaking the stem (also ampule or ampul).

3.3 *vial*—a small, usually cylindrical, vessel capable of closure, such as for medications, perfumes, essences, and samples.

### 3.4 Description of Term Specific to This Standard:

3.4.1 *Flip-Off type cap*—a plastic cap which must be removed to expose the injection port in the elastomeric and metal vial closure.

## 4. Requirements

4.1 Drugs in liquid form requiring dilution before parenteral administration shall not be packaged in containers that resemble a normal syringe. The design of such containers shall preclude direct intravenous line injection of the solution.

4.2 The labels on such containers (for example, vials and ampoules) shall bear the words “Dilute Before Use”, or similar warning, in type with initial capitals at least 2.5 mm in vertical height (10 point or larger) in bold font in contrasting ink, whenever space permits, preferably with a box printed in red (such as Pantone 805 or Warm Red). When copy space is not sufficient for 10 point type, the warning shall be at least equal in size to the name and strength designation of the drug.

4.3 Additional requirements specific for Potassium Chloride for Injection Concentrate as Mandated by the *United States Pharmacopeia*,<sup>5</sup> are as follows:

4.3.1 Immediately following the name, the label for Potassium Chloride for Injection Concentrate shall bear the boxed warning as shown in Fig. 1.

4.3.2 Vials containing potassium Chloride for Injection Concentrate shall be provided with a black metal closure (overseal) with a black cap. Both shall bear the words “Must be diluted” in legible type, in a color that stands out from its background (see Fig. 2).

4.3.3 Ampoules containing Potassium Chloride for Injection Concentrate shall be identified by a black band or series of black bands above the constriction (see Fig. 3).

4.3.4 Such black metal closures and black Flip-Off type caps and use of a black band or series of bands above the constrictor on an ampul shall only be used for Potassium Chloride for Injection Concentrate.

## 5. Significance and Use

5.1 Accidents continue to occur due to the user’s inability to easily identify vials and ampoules containing concentrated solutions of drugs which must be diluted before parenteral administration. The objective of this specification is to facilitate easy identification of such vials and ampoules.

## 6. Legibility Test

6.1 The copy for the proprietary name or established name

<sup>1</sup> This specification is under the jurisdiction of ASTM Committee D10 on Packaging and is the direct responsibility of Subcommittee D10.32 on Consumer Packages.

Current edition approved Sept. 10, 1995. Published March 1996. Originally published as D 5022 – 89. Last previous edition D 5022 – 89.

<sup>2</sup> “Flip-Off” is a registered trademark of the West Company.

<sup>3</sup> *Annual Book of ASTM Standards*, Vol 15.09.

<sup>4</sup> Available from Pantone Inc., 55 Knickerbocker Rd., Moonachie, NJ 07074.

<sup>5</sup> USP 23/NF18 1995, pp. 1254, 1651, Available from USPC, Inc, Order Processing Dept., 12601 Twinbrook Parkway, Rockville, MD 20852.



FIG. 1 Boxed Warning




FIG. 2 Vial Showing Black Flip-Off Type Cap and Black Closure for Potassium Chloride for Injection Concentrate




FIG. 3 Ampoule Showing Black Band Marking for Potassium Chloride for Injection Concentrate

of the drug, and the amount of the drug per unit, total volume and warning statement, shall be legible in a light of 215 lux (20 fc) at a distance of 500 mm (19.7 in.) by a person with 20/30 unaided or corrected vision.

## 7. Keywords

7.1 ampoules; drugs; label; vials

*The American Society for Testing and Materials takes no position respecting the validity of any patent rights asserted in connection with any item mentioned in this standard. Users of this standard are expressly advised that determination of the validity of any such patent rights, and the risk of infringement of such rights, are entirely their own responsibility.*

*This standard is subject to revision at any time by the responsible technical committee and must be reviewed every five years and if not revised, either reapproved or withdrawn. Your comments are invited either for revision of this standard or for additional standards and should be addressed to ASTM Headquarters. Your comments will receive careful consideration at a meeting of the responsible technical committee, which you may attend. If you feel that your comments have not received a fair hearing you should make your views known to the ASTM Committee on Standards, at the address shown below.*

*This standard is copyrighted by ASTM, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959, United States. Individual reprints (single or multiple copies) of this standard may be obtained by contacting ASTM at the above address or at 610-832-9585 (phone), 610-832-9555 (fax), or service@astm.org (e-mail); or through the ASTM website (www.astm.org).*